OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial
I'm LongbridgeAI, I can summarize articles.OKYO Pharma filed its 2026 Annual Report (Form 20-F), reporting $25 million in raised capital and a strengthened balance sheet with $20.6 million in cash. This funding supports the upcoming Phase 3 NEPTUNE trial for urcosimod, targeting neuropathic corneal pain. While analysts maintain a 'Buy' rating with a $5 target, TipRanks' AI tool rates the stock 'Neutral' due to weak financial fundamentals despite improved cost control.
The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( (OKYO) ).
On July 20, 2026, OKYO Pharma filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026 with the U.S. Securities and Exchange Commission, accompanied by a corporate update highlighting stronger finances and advancing clinical programs. During the year, the company raised about $25 million, including a February 2026 public offering that generated roughly $22 million in gross proceeds, leaving cash and equivalents of $20.6 million at fiscal year-end.
This reinforced balance sheet is expected to fund OKYO through completion of its FDA-agreed global NEPTUNE Phase 3 pivotal trial of urcosimod in neuropathic corneal pain. The trial, planned to start in the second half of 2026, will enroll around 111 patients in the U.S. and Europe in a single-dose regimen, and has been designed as a potential registrational study, underscoring the company’s strengthened position as it targets key clinical and regulatory milestones for its lead asset.
The most recent analyst rating on (OKYO) stock is a Buy
with a $5.00 price target.
To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock,
see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is primarily held down by weak financial fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Improved 2025 cost control and a debt-free balance sheet provide only limited offset.
To see Spark’s full report on OKYO stock,
click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and anterior segment eye diseases. Listed on the Nasdaq Capital Market, the company’s lead product candidate is urcosimod, a first-in-class chemerin peptide agonist targeting ocular immune and neuronal pathways to address significant unmet needs in neuropathic corneal pain.
Average Trading Volume: 81,296
Technical Sentiment Signal: Sell
Current Market Cap: $73.46M
For a thorough assessment of OKYO stock, go to TipRanks’ Stock Analysis page.